Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,017.64 -18.41 (-1.78%)
Streaming Delayed Price Updated: 2:02 PM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Eli Lilly's Landmark Trial Shows Major Psoriasis-Obesity Breakthrough With Taltz-Zepbound Combo ↗
Eli Lilly's latest trial results and new licensing agreement show promise in treating psoriasis, obesity, and kidney disease. 
Via Benzinga
News headline image
Health Care Sector (XLV) Shows Resilience Amid Tech Volatility and Strong Jobs Data
As the broader market grappled with a violent valuation reset in the technology sector, the health care industry emerged as a critical anchor for investors in early 2026. The Health Care Select Sector... 
Via MarketMinute
Topics Artificial Intelligence ETFs Earnings
News headline image
The Trillion-Dollar Pharmaceutical Giant: Eli Lilly Makes History as Weight-Loss Revolution Drives Unprecedented Growth
In a historic moment for the global healthcare industry, Eli Lilly and Company (NYSE:LLY) has officially cemented its position as the world’s first pharmaceutical company to surpass a $1 trillion... 
Via MarketMinute
Topics Earnings Economy
Eli Lilly & Co (NYSE:LLY) Combines Explosive Growth with a Bullish Technical Setup ↗
Via Chartmill
News headline image
Should You Buy the Vanguard S&P 500 ETF With the Stock Market Near a Record High? History Offers a Clear Answer ↗
Despite recent volatility, trends like artificial intelligence could fuel another strong year for the stock market. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Stocks
News headline image
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash ↗
Agios Pharmaceuticals targets rare blood disorders with a marketed anemia drug and a focused clinical-stage pipeline. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million ↗
This biotech firm develops precision therapies targeting rare genetic diseases, with a lead candidate focused on oncology indications. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake ↗
Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors. 
Via The Motley Fool
News headline image
Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More ↗
Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing multiple clinical-stage programs. 
Via The Motley Fool
News headline image
1 Reason I'd Buy Eli Lilly Stock and Never Sell ↗
A robust pipeline is essential for a buy-and-hold pharmaceutical stock. 
Via The Motley Fool
Topics Intellectual Property
News headline image
The Biotechnology Renaissance: AI and Capital Collide in a Multi-Trillion Dollar Pivot
As of February 17, 2026, the biotechnology sector is undergoing its most significant structural transformation in decades, a period now widely termed the "Biotechnology Renaissance." Following a... 
Via MarketMinute
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
NVO Stock Generates Retail Buzz After European Commission Approves 7.2 MG Once-Weekly Dose Of Wegovy Injection ↗
The approval follows a positive recommendation from the European Medicines Agency and is supported by data from clinical trials involving more than 1,400 participants. 
Via Stocktwits
Topics Lawsuit
News headline image
Hims & Hers Faces New Hurdle In Weight-Loss Brawl With Novo Nordisk ↗
Novo Nordisk and the FDA are both mounting pressure on Hims & Hers Health and other GLP-1 compounders. 
Via Investor's Business Daily
Topics Lawsuit
News headline image
2026 Could Be a Big Year for Viking Therapeutics. Time to Buy? ↗
Viking should have plenty of news to share with investors this year. 
Via The Motley Fool
News headline image
Eli Lilly's Experimental Cancer Drug Cuts Recurrence Risk In Early-Stage Lung Cancer Patients ↗
Eli Lilly's lung cancer trial shows lower recurrence risk and strong survival benefit in early-stage patients. 
Via Benzinga
News headline image
Nasdaq, S&P 500 Futures Lower As AI Disruption Fears Linger: Why AAPL, ZIM, OCUL, NCLH Are On Traders' Radar Today ↗
Wall Street resumed trade after the Presidents’ Day break to find a market still grappling with the ‘AI disruption’ trade. 
Via Stocktwits
Topics Artificial Intelligence ETFs Economy
News headline image
Novo Nordisk's New Diabetes Drug Outshines Ozempic: Is The Stock a Buy? ↗
Novo Nordisk's plan to gain ground in the GLP-1 space is slowly taking shape. 
Via The Motley Fool
News headline image
Liberty One Cuts Its Lamb Weston Position in Half With $32 Million Sale ↗
Lamb Weston is a global leader in frozen potato products, serving both retail and foodservice markets with a diversified brand portfolio. 
Via The Motley Fool
Topics Economy Regulatory Compliance Supply Chain
News headline image
Forget AI Stocks: This Pharma Giant Is Using AI to Dominate Drug Discovery ↗
And there's more than one way to monetize this technology. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
The Smartest Growth ETF to Buy With $1,000 Right Now. (Hint: It Has Averaged Annual Gains of 18.6% Over the Past 10 Years.) ↗
It's an easy way to quickly own 150-plus companies growing at a solid clip. 
Via The Motley Fool
Topics ETFs
News headline image
Eli Lilly Just Delivered Great News for Investors -- and It Goes Beyond Weight-Loss Drugs ↗
Eli Lilly isn't a one-trick pony. 
Via The Motley Fool
News headline image
What Is One of the Best Pharmaceutical Stocks to Own for the Next 10 Years? ↗
Eli Lilly continues to pursue smart acquisitions for the long term. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Got $500? 2 Pharma Stocks to Buy and Hold Forever. ↗
Growth, value, or both? 
Via The Motley Fool
News headline image
Novo Nordisk To Meet Wegovy Pill Demand In US Before Expanding To Avoid Supply Shortage, Says CEO Doustdar ↗
Novo is looking to ensure the U.S. market is supplied before choosing another country to scale in, Doustdar said in an interview with CNBC. 
Via Stocktwits
Topics Lawsuit
News headline image
"Blowout" Jobs Report Ignites 2026 Growth Hopes as Unemployment Hits 4.3% Floor
The U.S. labor market kicked off 2026 with an unexpected surge, as the January nonfarm payrolls report shattered analyst expectations and provided a much-needed jolt to the economic outlook. Adding... 
Via MarketMinute
Topics Artificial Intelligence Economy Workforce
News headline image
Hospitals Stand Tall: Healthcare Sector Becomes Safe Haven Amid "Warsh Shock" and Tech Volatility
In a day defined by sharp reversals and a fundamental recalibration of market leadership, the healthcare sector emerged as the primary beneficiary of a massive capital rotation on February 13, 2026.... 
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
News headline image
Did Eli Lilly Just Make a Deal for Its Next Blockbuster Drug? ↗
Eli Lilly announced an acquisition of an innovative new autoimmune drug. 
Via The Motley Fool
News headline image
The Great 2026 Divergence: Tech Titans Rise on AI Execution While Healthcare Reaps a Regulatory Whirlwind
As the opening bell rang on February 13, 2026, the divergence between the U.S. technology and healthcare sectors reached a historic fever pitch, signaling a fundamental shift in how markets price... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Meet the 6.3% Yield Dividend Stock That Could Soar in 2026 ↗
Pfizer's long-acting GLP-1 weight loss candidate could set the stage for a stock rally. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Eli Lilly Builds $1.5 Billion Inventory Of Experimental Weight-Loss Pill As FDA Decision Looms ↗
Eli Lilly and Company (NYSE: LLY) has stockpiled $1.5 billion worth of inventory of its experimental oral weight-loss drug, orforglipron, according to a regulatory filing on Thursday. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.